BridgeBio Pharma
Develops and commercializes genetically targeted medicines through a decentralized portfolio model.
Something off on this page? Send us feedback.
Profile
Develops medicines for genetic diseases through asset-focused teams backed by shared clinical, regulatory, and commercial infrastructure. U.S. sales of Attruby for transthyretin amyloid cardiomyopathy provide most revenue, while BBP-418, encaleret, and oral infigratinib form the late-stage regulatory pipeline.
Develops and commercializes medicines for genetically defined diseases through a decentralized portfolio model. Attruby, an acoramidis treatment for transthyretin amyloid cardiomyopathy, is sold directly in the United States; the same medicine is marketed as Beyonttra abroad, largely through partners including Bayer in Europe and Alexion in Japan. Late-stage work centers on BBP-418 for limb-girdle muscular dystrophy, encaleret for autosomal dominant hypocalcemia, and oral infigratinib for achondroplasia, all under U.S. regulatory review.
Pairs asset-focused scientific teams with shared clinical, regulatory, finance, and commercial infrastructure, allowing several programs to advance in parallel. Commercial revenue currently comes primarily from U.S. Attruby sales. The business remains substantially dependent on acoramidis, relies on partners outside the United States and third parties for all manufacturing, and requires regulatory approval and payer coverage for each pipeline medicine.
Company facts
Key statistics
Year to date −2.1% · Average volume (30d) 2.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 12, 2026 | Truist Financial | Target | $102 | $107 | |
| Aug 12, 2026 | Canaccord Genuity | Reiterate | Buy | $104 | $106 |
| Aug 11, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $110 | |
| Aug 11, 2026 | Morgan Stanley | Reiterate | Overweight | $98 | $97 |
| Aug 11, 2026 | Wells Fargo | Reiterate | Overweight | $88 | $102 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.58 | −$0.78 | −35.5% | $220.9M | $243.7M | +10.3% | −1.15% |
| May 7, 2026Q1 FY26 | −$0.70 | −$0.84 | −20.0% | $178.1M | $194.5M | +9.2% | −0.09% |
| Feb 24, 2026Q4 FY25 | −$0.71 | −$1.00 | −40.2% | $146.8M | $154.2M | +5.0% | −2.59% |
| Oct 29, 2025Q3 FY25 | −$0.88 | −$0.95 | −8.0% | $148.2M | $120.7M | −18.5% | −4.88% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $116.6M | $110.6M | $120.7M | $154.2M | $194.5M | $222.4M | |
| Gross profit | $114.0M | $106.9M | $114.1M | $138.8M | $184.1M | $207.4M | |
| Operating income | −$104.4M | −$134.3M | −$145.2M | −$185.2M | −$106.0M | −$107.1M | |
| Net income | −$167.4M | −$181.9M | −$182.7M | −$197.2M | −$164.0M | −$152.2M | |
| Diluted EPS | −$0.88 | −$0.95 | −$0.96 | −$1.00 | −$0.84 | −$0.78 | |
| Gross margin | 97.7% | 96.7% | 94.6% | 90.0% | 94.6% | 93.2% | |
| Operating margin | -89.5% | -121.4% | -120.3% | -120.1% | -54.5% | -48.1% |
Fiscal years (4-quarter sums)FY21 $69.7M · FY22 $77.6M · FY23 $9.3M · FY24 $221.9M · FY25 $502.1M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $720.2M · Total debt $2.49B · Total assets $1.22B · Shareholders' equity −$2.52B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 195.86M · Float 169.19M · 86.4% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 14.11M | 7.20% | 13F | Aug 14, 2026 |
| Kohlberg Kravis Roberts & Co. L.P. | 13.26M | 6.77% | 13F | Aug 14, 2026 |
| KKR Genetic Disorder L.P. · 10 percent owner | 13.26M | 6.77% | Form 4 | May 14, 2025 |
| Janus Henderson Group PLC | 13.18M | 6.80% | 13G | May 15, 2026 |
| Farallon Capital Management LLC | 10.74M | 5.49% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Neil Kumar | director, officer: Chief Executive Officer | −10,000 | $84.03 |
| Aug 18, 2026 | Neil Kumar | director, officer: Chief Executive Officer | −34,980 | $82.53 |
| Jul 30, 2026 | Maricel Apuli | officer: Chief Accounting Officer | −2,000 | $80.06 |
| Jul 9, 2026 | Jennifer E. Cook | director | −148,589 | $88.54 |
| Jul 9, 2026 | Andrea Ellis | director | −17,167 | $84.00 |
Peers
- Pfizer
ATTR-CM incumbent; tafamidis (Vyndamax) holds 75% of ATTR-CM prescriptions.
- Alnylam Pharmaceuticals
FDA-approved ATTR-CM RNAi silencer (Amvuttra) growing fast on mortality data.
- BioMarin
Approved achondroplasia incumbent (Voxzogo) facing infigratinib oral challenge.
- Ionis Pharmaceuticals
ASO TTR silencer; Wainua approved for ATTR-PN, ATTR-CM Phase 3 data H2 2026.
- Intellia Therapeutics
One-time CRISPR ATTR gene editor (nex-z) in Phase 3; hold lifted March 2026.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Alnylam Pharmaceuticals | $240.00 | +1.22% | $31.73B | 40.1 | 26.7 | 6.6 | +66.9% |
| BioMarin | $64.67 | +0.02% | $12.50B | 165.8 | 10.4 | 3.7 | +19.9% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Median | 40.1 | 10.4 | 6.6 | +2.6% |